Linked Life Data

11268328

Source:http://linkedlifedata.com/resource/pubmed/id/11268328

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11 Suppl
pubmed:dateCreated
2001-3-27
pubmed:abstractText
In the last two decades autologous hematopoietic stem cell transplantation (HSCT) has been increasingly used in the treatment of several poor risk solid tumors of childhood. Examples are recurrent or resistant cancers, metastatic presentation at diagnosis, incomplete surgical resection, unfavorable histologic and biological features. Results from the Children's Cancer Group randomized trial confirm the data from retrospective studies which reported the superiority of HSCT over standard chemotherapy for neuroblastoma. Several retrospective analyses support the use of HSCT in Ewing's sarcoma and in some brain tumors. No evidence of utility has been reported for rhabdomyosarcoma. The most widely utilized source of stem cells is peripheral blood, while there are conflicting data regarding the use of total body irradiation and purging of stem cells.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0390-6078
pubmed:author
pubmed:issnType
Print
pubmed:volume
85
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
66-70
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
High dose therapy and autologous hematopoietic stem cell transplantation in poor risk solid tumors of childhood.
pubmed:affiliation
BMT Unit, Department of Hematology/Oncology, G. Gaslini Children's Hospital IRCCS, Iargo G. Gaslini 5, 16148 Genova, Italy.
pubmed:publicationType
Journal Article, Review